
Pandemic and All-Hazards Preparedness Act (PAHPA) Policy Brief

Employer Investments in Digital, Whole-Person Health for Substance Use Disorders

Toward a National Action Plan for Achieving Diversity in Clinical Trials

Milken Institute Announces Key Initiatives at the 2024 Global Conference to Shape the Future of Health

Comments on FDA’s Draft Guidance for Industry, Investigators, and Other Stakeholders on Decentralized Clinical Trials for Drugs, Biological Products, and Devices - Docket ID FDA-2022-D-2870
